Portfolio Building Block World Pharma and… (PBPH) Holdings
PBPH holdings summary
as of Oct 24, 2026- Holdings
- 52 positions listed
- Top 10 weight
- 64.0% of net assets
- Effective holdings
- 16 equal-weight equivalent
- Largest holding
- LLY 16.17% Eli Lilly and Company
- Annual turnover
- — of the portfolio traded
All PBPH holdings
| # | Name | ||||||
|---|---|---|---|---|---|---|---|
| 1 | LLY | Eli Lilly and Company | Healthcare | 16.17% | $181.9M | $1.12T | 42.2 |
| 2 | JNJ | Johnson & Johnson | Healthcare | 9.87% | $111.0M | $615.87B | 38.8 |
| 3 | ABBV | AbbVie Inc. | Healthcare | 7.38% | $83.1M | $504.37B | 80.6 |
| 4 | MRK | Merck & Co., Inc. | Healthcare | 5.20% | $58.5M | $360.08B | 115.8 |
| 5 | ROP | Roche Holding AG | Healthcare | 5.19% | $58.4M | — | — |
| 6 | AZN | AstraZeneca PLC | Healthcare | 4.67% | $52.6M | — | — |
| 7 | AMGN | Amgen Inc. | Healthcare | 4.29% | $48.3M | $233.82B | 26.9 |
| 8 | NOVN | Novartis AG | Healthcare | 4.05% | $45.6M | — | — |
| 9 | GILD | Gilead Sciences, Inc. | Healthcare | 3.83% | $43.1M | $193.67B | — |
| 10 | PFE | Pfizer Inc. | Healthcare | 3.35% | $37.7M | $168.60B | 38.9 |
| 11 | VRTX | Vertex Pharmaceuticals Incorporated | Healthcare | 2.58% | $29.0M | $126.66B | 28.9 |
| 12 | 0QIU | Novo Nordisk A/S Class B | Other | 2.54% | $28.6M | — | — |
| 13 | BMY | Bristol-Myers Squibb Company | Healthcare | 2.51% | $28.3M | $122.05B | 13.2 |
| 14 | GSK | GSK plc | Healthcare | 1.93% | $21.8M | — | — |
| 15 | SAN | Sanofi SA | Healthcare | 1.91% | $21.4M | — | — |
| 16 | REGN | Regeneron Pharmaceuticals, Inc. | Healthcare | 1.61% | $18.1M | $81.41B | 19.6 |
| 17 | CSL | CSL Ltd | Healthcare | 1.38% | $15.5M | — | — |
| 18 | MRNA | Moderna, Inc. | Healthcare | 1.37% | $15.4M | $87.04B | — |
| 19 | 4502 | Takeda Pharmaceutical Co. Ltd. | Healthcare | 1.24% | $14.0M | — | — |
| 20 | NTRA | Natera, Inc. | Healthcare | 1.11% | $12.5M | $56.71B | — |
| 21 | ARGX | Argen-X | Healthcare | 1.10% | $12.4M | — | — |
| 22 | BAYN | Bayer AG NA | Healthcare | 0.98% | $11.0M | — | — |
| 23 | TEVA | Teva Pharmaceutical Industries Ltd | Healthcare | 0.90% | $10.1M | — | — |
| 24 | ILMN | Illumina, Inc. | Healthcare | 0.79% | $8.9M | $39.64B | 49.0 |
| 25 | SDZ | Sandoz Group AG | Healthcare | 0.79% | $8.9M | — | — |
| 26 | BIIB | Biogen Inc. | Healthcare | 0.79% | $8.9M | $34.37B | 41.3 |
| 27 | UCB | UCB SA | Healthcare | 0.77% | $8.7M | — | — |
| 28 | 4578 | Otsuka Holdings Ltd | Healthcare | 0.67% | $7.6M | — | — |
| 29 | ZTS | Zoetis Inc. | Healthcare | 0.66% | $7.5M | $32.80B | 13.1 |
| 30 | RVMD | Revolution Medicines, Inc. | Healthcare | 0.66% | $7.5M | $38.14B | — |
| 31 | 4568 | Daiichi Sankyo Co. Ltd. | Healthcare | 0.60% | $6.8M | — | — |
| 32 | ALNY | Alnylam Pharmaceuticals, Inc. | Healthcare | 0.59% | $6.7M | $31.02B | 39.1 |
| 33 | 4503 | Astellas Pharma Inc. | Healthcare | 0.56% | $6.3M | — | — |
| 34 | HLN | Haleon PLC | Healthcare | 0.55% | $6.2M | — | — |
| 35 | 4519 | Chugai Pharmaceutical Co. Ltd. | Healthcare | 0.55% | $6.1M | — | — |
| 36 | UTHR | United Therapeutics Corporation | Healthcare | 0.50% | $5.7M | $22.87B | 19.1 |
| 37 | GEN | Genmab A/S | Other | 0.49% | $5.6M | — | — |
| 38 | RPRX | Royalty Pharma plc | Healthcare | 0.49% | $5.5M | $35.22B | 32.4 |
| 39 | INCY | Incyte Corporation | Healthcare | 0.46% | $5.2M | $22.92B | 14.4 |
| 40 | 0O14 | MERCK Kommanditgesellschaft auf Aktien | Healthcare | 0.45% | $5.0M | — | — |
| 41 | VTRS | Viatris Inc. | Healthcare | 0.41% | $4.6M | $21.43B | — |
| 42 | INSM | Insmed Incorporated | Healthcare | 0.40% | $4.5M | $21.02B | — |
| 43 | ROIV | Roivant Sciences Ltd. | Healthcare | 0.36% | $4.1M | $24.22B | — |
| 44 | EXEL | Exelixis, Inc. | Healthcare | 0.34% | $3.9M | $15.42B | 19.6 |
| 45 | NBIX | Neurocrine Biosciences, Inc. | Healthcare | 0.30% | $3.4M | $13.79B | 19.9 |
| 46 | RO | Roche Holding AG | Healthcare | 0.29% | $3.2M | — | — |
| 47 | JAZZ | Jazz Pharmaceuticals plc | Healthcare | 0.27% | $3.1M | $13.65B | 14.4 |
| 48 | 4507 | Shionogi & Co. Ltd. | Healthcare | 0.27% | $3.1M | — | — |
| 49 | GALD | Galderma Group N | Healthcare | 0.27% | $3.0M | — | — |
| 50 | ELAN | Elanco Animal Health Incorporated | Healthcare | 0.25% | $2.8M | $11.76B | — |
| 51 | BBIO | BridgeBio Pharma, Inc. | Healthcare | 0.22% | $2.5M | $12.98B | — |
| 52 | BMRN | BioMarin Pharmaceutical Inc. | Healthcare | 0.22% | $2.5M | $10.58B | 147.8 |
Weights as a percentage of net assets. Value held = weight × net assets ($1.13B). Market cap and P/E from each company's latest fundamentals (U.S.-listed stocks).
PBPH sector breakdown
Sum of the weights of the holdings in each sector.
PBPH top industries
PBPH overlap with other ETFs
| ETF | Fund | Overlap | Shared holdings | Expense ratio |
|---|---|---|---|---|
| IYH | iShares U.S. Healthcare ETF | 59.6% | 29 of 99 | 0.39% |
| XLV | Health Care Select Sector SPDR Fund | 56.5% | 16 of 60 | 0.09% |
| TRUH | VanEck Healthcare TruSector ETF | 55.9% | 16 of 60 | — |
| MEDX | Horizon Kinetics Medical ETF | 53.6% | 13 of 30 | 0.80% |
| FHLC | Fidelity MSCI Health Care ETF | 52.7% | 29 of 334 | 0.07% |
| VHT | Vanguard Health Care ETF | 52.5% | 28 of 406 | 0.10% |
Overlap = sum over shared holdings of the smaller of the two weights. 100% means identical portfolios.
About the PBPH portfolio
Portfolio Building Block World Pharma and… holds 52 positions. The ten largest make up 64.0% of the fund and the top 50 98.7%, so it behaves like a portfolio of about 16 equally weighted stocks. The biggest positions are Eli Lilly and Company (16.17%), Johnson & Johnson (9.87%), AbbVie Inc. (7.38%), Merck & Co., Inc. (5.20%), Roche Holding AG (5.19%).
By sector, Healthcare is 96.1%, Other is 3.0%. Holdings data is from the fund's latest portfolio as reported by EODHD on October 24, 2026; positions change as the fund rebalances.
Related: PBPH chart, PBPH dividends, PBPH valuation, PBPH overview.
PBPH holdings FAQ
How many holdings does PBPH have?
PBPH holds 52 positions as of October 24, 2026.
What are the top 10 holdings of PBPH?
The ten largest holdings are Eli Lilly and Company (16.17%), Johnson & Johnson (9.87%), AbbVie Inc. (7.38%), Merck & Co., Inc. (5.20%), Roche Holding AG (5.19%), AstraZeneca PLC (4.67%), Amgen Inc. (4.29%), Novartis AG (4.05%), Gilead Sciences, Inc. (3.83%), Pfizer Inc. (3.35%). Together they are 64.0% of the fund.
What percentage of PBPH is Eli Lilly and Company?
Eli Lilly and Company is the largest holding at 16.17% of net assets, about $181.9M of the fund's $1.13B.
How concentrated is PBPH?
The top 10 holdings are 64.0% of the fund. By the effective number of holdings (1 divided by the sum of squared weights) PBPH behaves like a portfolio of about 16 equally weighted stocks.